<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04746053</url>
  </required_header>
  <id_info>
    <org_study_id>RC31/20/0124</org_study_id>
    <secondary_id>2020-A02800-39</secondary_id>
    <nct_id>NCT04746053</nct_id>
  </id_info>
  <brief_title>Ovarian Function and Gynecological Profile of Patients Carrying a Pathogenic Variant of the HNF1B Gene (GYN-HNF1)</brief_title>
  <acronym>GYN-HNF1</acronym>
  <official_title>Study of Ovarian Function and Gynecological Profile of Patients Carrying a Pathogenic Variant of the HNF1B Gene (GYN-HNF1)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to study the ovarian function of patients with hepatocyte&#xD;
      nuclear factor-1beta (HNF1B) abnormality, followed in the reference centers of Toulouse and&#xD;
      Paris University Hospitals. The secondary objectives are to know the gynecological profile of&#xD;
      these patients.&#xD;
&#xD;
      A dosage of anti-mullerian hormone (AMH) will be added to the usual balance, whatever the&#xD;
      phase of the cycle and a pelvic ultrasound will be performed by the same operator by center.&#xD;
      Patients will be received in a dedicated consultation to complete a questionnaire on&#xD;
      gynecological and obstetric history, as well as their personal and family history. There will&#xD;
      be no gynecological examination during this consultation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HNF1B mutations can be responsible for genital malformations associated with renal&#xD;
      development abnormalities. HNF1b is also a candidate gene involved in the development of the&#xD;
      renal tract and the Mullerian system but there is no data in the literature regarding the&#xD;
      ovarian function and clinical gynecological profile of these patients.&#xD;
&#xD;
      The main objective of this study is to study the ovarian function of patients with HNF1B&#xD;
      abnormality, followed in the reference centers of Toulouse and Paris University Hospitals.&#xD;
      The secondary objectives are to know the gynecological profile of these patients.&#xD;
&#xD;
      A dosage of AMH will be added to the usual balance, whatever the phase of the cycle and a&#xD;
      pelvic ultrasound will be performed. Patients will be received in a dedicated consultation to&#xD;
      complete a questionnaire on gynecological and obstetric history, as well as their personal&#xD;
      and family history. There will be no gynecological examination during this consultation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2021</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>serum level of Antimullerian Hormone levels</measure>
    <time_frame>day 1</time_frame>
    <description>serum level of antimullerian hormone levels in ng/mL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ultrasound result</measure>
    <time_frame>day 1</time_frame>
    <description>ultrasound (pelvic or vaginal) will allow the team to look at whether or not there is a genital defect and the type of defect.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Genital Diseases, Female</condition>
  <arm_group>
    <arm_group_label>patient with a mutation in the HNF1B gene</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patient with a mutation in the HNF1B gene and which are followed in the reference centers</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pelvic ultrasound</intervention_name>
    <description>Pelvic or vaginal ultrasound</description>
    <arm_group_label>patient with a mutation in the HNF1B gene</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>blood sample</intervention_name>
    <description>blood sample (5ml)</description>
    <arm_group_label>patient with a mutation in the HNF1B gene</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Girls from 12 years of age carrying a pathogenic variant of the HNF1 B gene and&#xD;
             monitored in the reference center for rare renal diseases&#xD;
&#xD;
          -  Person affiliated or beneficiary of a social security scheme.&#xD;
&#xD;
          -  Free, informed and written consent signed by the participant or her legal&#xD;
             representative if a minor patient and the investigator (at the latest on the day of&#xD;
             inclusion and before any examination required by the research).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Woman unable to answer&#xD;
&#xD;
          -  Pregnant or breastfeeding woman&#xD;
&#xD;
          -  Refusal of participation by the patient or her legal representative&#xD;
&#xD;
          -  Person under a protection system for adults (such as safeguard of justice,&#xD;
             guardianship or curatorship)&#xD;
&#xD;
          -  History of chemotherapy, radiotherapy, brachytherapy&#xD;
&#xD;
          -  History of ovarian endometrium&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Catherine PIENKOWSKI, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Toulouse</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Catherine PIENKOWSKI, MD</last_name>
    <phone>05 34 55 85 53</phone>
    <phone_ext>33</phone_ext>
    <email>pienkowski.c@chu-toulouse.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Pitié Salpêtrière Hospital -</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Zeina Chakhtoura, MD</last_name>
      <phone>01 42 16 02 20</phone>
      <phone_ext>+33</phone_ext>
      <email>zeina.chakhtoura@psl.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Zeina Chakhtoura, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Necker Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75743</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Sabrina Da costa, Dr</last_name>
      <email>sabrina.dacosta@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Sabrina Da costa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alaa Cheikhelard, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Toulouse University Hospital</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Catherine PIENKOWSKI, MD</last_name>
      <phone>5 34 55 85 53</phone>
      <phone_ext>+33</phone_ext>
      <email>pienkowski.c@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Catherine PIENKOWSKI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Audrey Cartault, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Perrine Ernoult, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stéphane Decramer, PH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dominique Chauveau, PH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stanislas Faguer, PH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Edghill EL, Bingham C, Ellard S, Hattersley AT. Mutations in hepatocyte nuclear factor-1beta and their related phenotypes. J Med Genet. 2006 Jan;43(1):84-90. Epub 2005 Jun 1.</citation>
    <PMID>15930087</PMID>
  </reference>
  <reference>
    <citation>Lindner TH, Njolstad PR, Horikawa Y, Bostad L, Bell GI, Sovik O. A novel syndrome of diabetes mellitus, renal dysfunction and genital malformation associated with a partial deletion of the pseudo-POU domain of hepatocyte nuclear factor-1beta. Hum Mol Genet. 1999 Oct;8(11):2001-8.</citation>
    <PMID>10484768</PMID>
  </reference>
  <reference>
    <citation>Oram RA, Edghill EL, Blackman J, Taylor MJ, Kay T, Flanagan SE, Ismail-Pratt I, Creighton SM, Ellard S, Hattersley AT, Bingham C. Mutations in the hepatocyte nuclear factor-1β (HNF1B) gene are common with combined uterine and renal malformations but are not found with isolated uterine malformations. Am J Obstet Gynecol. 2010 Oct;203(4):364.e1-5. doi: 10.1016/j.ajog.2010.05.022. Epub 2010 Jul 15.</citation>
    <PMID>20633866</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 4, 2021</study_first_submitted>
  <study_first_submitted_qc>February 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 9, 2021</study_first_posted>
  <last_update_submitted>February 4, 2021</last_update_submitted>
  <last_update_submitted_qc>February 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>gene HNF1b mutation</keyword>
  <keyword>ovarian function</keyword>
  <keyword>genital malformations</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

